Bio-Path Holdings Inc (BPTH)

1.37
0.01 0.74
NASDAQ : Health Care
Prev Close 1.36
Open 1.36
Day Low/High 1.34 / 1.38
52 Wk Low/High 1.00 / 3.19
Volume 27.00K
Avg Volume 208.20K
Exchange NASDAQ
Shares Outstanding 95.65M
Market Cap 132.95M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bio-Path Holdings Announces Collaboration With Thomas Jefferson University For Systemic Antisense Immunotherapy Treatment For Brain Cancer

Bio-Path Holdings Announces Collaboration With Thomas Jefferson University For Systemic Antisense Immunotherapy Treatment For Brain Cancer

Sponsored Research Agreement will Evaluate DNAbilize™ Technology as a Cancer Vaccine to Activate Patients' Immune Systems to Fight Cancer

Bio-Path Holdings Reports Promising Data From Phase I And Phase II Clinical Trials Of BP1001 In Blood Cancers Presented At ASCO 2016

Bio-Path Holdings Reports Promising Data From Phase I And Phase II Clinical Trials Of BP1001 In Blood Cancers Presented At ASCO 2016

Five of six evaluable patients achieved remission in safety segment of the Phase II combination therapy trial of BP1001, including three complete remissions and two partial remissions

Bio-Path Holdings Reports First Quarter 2016 Financial Results

Bio-Path Holdings Reports First Quarter 2016 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Announces Research Collaboration On Autoimmune Indication With The University Of Texas Southwestern Medical Center

Bio-Path Holdings Announces Research Collaboration On Autoimmune Indication With The University Of Texas Southwestern Medical Center

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid drugs,...

Bio-Path Holdings Reports Fiscal Year 2015 Operational And Financial Results

Bio-Path Holdings Reports Fiscal Year 2015 Operational And Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery technology to develop a portfolio of targeted nucleic acid cancer drugs, today...

Bio-Path Holdings Announces Pancreatic Cancer Research Collaboration With Leading Oncology Institution

Bio-Path Holdings Announces Pancreatic Cancer Research Collaboration With Leading Oncology Institution

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer...

Bio-Path Holdings To Present At The 28th Annual ROTH Conference

Bio-Path Holdings To Present At The 28th Annual ROTH Conference

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer...

Bio-Path Holdings Announces Completion Of The Safety Segment Of The Phase II Clinical Trial Of BP1001 In Acute Myeloid Leukemia

Bio-Path Holdings Announces Completion Of The Safety Segment Of The Phase II Clinical Trial Of BP1001 In Acute Myeloid Leukemia

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer...

Bio-Path Holdings To Present At The 18th Annual BIO CEO & Investor Conference

Bio-Path Holdings To Present At The 18th Annual BIO CEO & Investor Conference

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer...

Bio-Path Holdings To Present At Biotech Showcase™ 2016

Bio-Path Holdings To Present At Biotech Showcase™ 2016

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer...

Bio-Path Holdings' Data From Phase I And Safety Segment Of Phase II Clinical Trials In Blood Cancers Presented At 57th American Society Of Hematology (ASH) Annual Meeting

Bio-Path Holdings' Data From Phase I And Safety Segment Of Phase II Clinical Trials In Blood Cancers Presented At 57th American Society Of Hematology (ASH) Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer...

Bio-Path Holdings Reports Third Quarter 2015 Operational And Financial Results

Bio-Path Holdings Reports Third Quarter 2015 Operational And Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery technology to develop a portfolio of targeted nucleic acid cancer drugs, today...

Bio-Path Holdings' Data To Be Presented At 57th American Society Of Hematology (ASH) Annual Meeting

Bio-Path Holdings' Data To Be Presented At 57th American Society Of Hematology (ASH) Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Dr.

Bio-Path Holdings To Present At The 14th Annual BIO Investor Forum

Bio-Path Holdings To Present At The 14th Annual BIO Investor Forum

Bio-Path Holdings, Inc., (NASDAQ:BPTH) (Bio-Path), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer,...

Bio-Path Holdings Announces Successful Completion Of Cohort 7 Of Phase Ib Clinical Trial Evaluating Liposomal Grb-2 In Acute Myeloid Leukemia

Bio-Path Holdings Announces Successful Completion Of Cohort 7 Of Phase Ib Clinical Trial Evaluating Liposomal Grb-2 In Acute Myeloid Leukemia

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced the successful completion of Cohort 7 of its Phase Ib...

Bio-Path Holdings To Present At The 17th Annual Rodman & Renshaw Global Investment Conference

Bio-Path Holdings To Present At The 17th Annual Rodman & Renshaw Global Investment Conference

Bio-Path Holdings, Inc., (NASDAQ: BPTH) (Bio-Path), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive...

Bio-Path Holdings Forms Scientific Advisory Board To Support Advancement Of Liposomal Grb-2 In Blood Cancers

Bio-Path Holdings Forms Scientific Advisory Board To Support Advancement Of Liposomal Grb-2 In Blood Cancers

Bio-Path Holdings, Inc., (NASDAQ: BPTH) (Bio-Path), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced the formation of its inaugural Scientific Advisory Board...

Bio-Path Holdings Reports Second Quarter 2015 Operational And Financial Results

Bio-Path Holdings Reports Second Quarter 2015 Operational And Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary liposomal delivery technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced operational...

Bio-Path Holdings Announces

Bio-Path Holdings Announces "At-the-Market" Offering With Cantor Fitzgerald

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it has established an "at-the-market" ("ATM") program...

Short Interest Makes 39.2% Move For BPTH

Short Interest Makes 39.2% Move For BPTH

The most recent short interest data has been released by the NASDAQ for the 05/15/2015 settlement date, which shows a 817,213 share increase in total short interest for Bio-Path Holdings, Inc. , to 2,901,229, an increase of 39.21% since 04/30/2015.

Bio-Path Holdings Reports First Quarter 2015 Operational And Financial Results

Bio-Path Holdings Reports First Quarter 2015 Operational And Financial Results

Bio-Path Holdings, Inc., (NASDAQ: BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the quarter ended...